2021
Anti-seizure medications and efficacy against focal to bilateral tonic-clonic seizures: A systematic review with relevance for SUDEP prevention
Cutillo G, Tolba H, Hirsch LJ. Anti-seizure medications and efficacy against focal to bilateral tonic-clonic seizures: A systematic review with relevance for SUDEP prevention. Epilepsy & Behavior 2021, 117: 107815. PMID: 33640562, DOI: 10.1016/j.yebeh.2021.107815.Peer-Reviewed Original ResearchConceptsAnti-seizure medicationsBilateral tonic-clonic seizuresTonic-clonic seizuresSUDEP preventionSystematic reviewPlacebo-controlled clinical trialFocal impaired awareness seizuresRisk of SUDEPSudden unexpected deathMajor risk factorAwareness seizuresRisk factorsClinical trialsUnexpected deathFBTCSHigh dosesSeizuresStrong associationSUDEPPreventionMedicationsTiagabineEfficacyLamotrigineBrivaracetam
2007
The Status of Intravenous Valproate for Status
Hirsch LJ. The Status of Intravenous Valproate for Status. Epilepsy Currents 2007, 7: 96-98. PMID: 17694164, PMCID: PMC1941916, DOI: 10.1111/j.1535-7511.2007.00185.x.Peer-Reviewed Original Research
2006
Topiramate for the treatment of epilepsy and other nervous system disorders
van Passel L, Arif H, Hirsch LJ. Topiramate for the treatment of epilepsy and other nervous system disorders. Expert Review Of Neurotherapeutics 2006, 6: 19-31. PMID: 16466308, DOI: 10.1586/14737175.6.1.19.Peer-Reviewed Original ResearchConceptsPossible neuroprotective agentsTroublesome adverse effectsOral hypoglycemic agentsCognitive side effectsTreatment of epilepsyNervous system disordersNeuropathic painMigraine prophylaxisNeuroprotective agentsHypoglycemic agentsSystem disordersSide effectsBroad-spectrum efficacyBipolar disorderLow dosesPsychiatric conditionsTopiramateSubstance dependenceAdverse effectsEpilepsyDisordersEfficacySpectrum efficacyMonotherapyProphylaxis